Last edition
News about "Ionis zilganersen NDA"
FDA Accepts Ionis' Zilganersen NDA for Priority Review in AxD
Ionis’ zilganersen NDA for Alexander disease has been accepted by the FDA for Priority Review, with a PDUFA target action date set for 22nd September, 2026, marking a key regulatory milestone for the potential treatment.
Ionis Zilganersen NDA | 24/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members